USA - engelsk - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - trimethoprim 1 mg in 1 ml - trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenza and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - trimethoprim, quantity: 300 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; povidone; sodium starch glycollate; purified talc; magnesium stearate - this product approved for registration as a variation of a product accepted for inclusion in the artg as 'currently supplied' at the commencement of the act. indications are held in artg paper records. previous product number aust r 17577 and 43120. product information not reviewed. indications as at 5 december 1984 : treatment of acute urinary tract infections caused by sensitive organisms.

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. swensweg 5 2031 ga haarlem - trimethoprim 100 mg/stuk - tablet - cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; magnesiumstearaat (e 470b) ; povidon (e 1201) ; siliciumdioxide (e 551), - trimethoprim

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. swensweg 5 2031 ga haarlem - trimethoprim 300 mg/stuk - tablet - cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; magnesiumstearaat (e 470b) ; povidon (e 1201) ; siliciumdioxide (e 551), - trimethoprim

USA - engelsk - NLM (National Library of Medicine)

watson labs - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - tablet - 100 mg - for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli, proteus mirabilis, klebsiella pneumoniae, enterobacter species and coagulase-negative staphylococcus species, including s. saprophyticus. cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the results of these tests. trimethoprim tablets are contraindicated in individuals hypersensitive to trimethoprim and in those with documented megaloblastic anemia due to folate deficiency.

Storbritannia - engelsk - myHealthbox

milpharm limited - trimethoprim - tablets - 200mg - systemic antibacterial - treatment of susceptible infections caused by trimethoprim sensitive organisms including most gram-positive and gram-negative aerobic organisms, including haemophilus influenzae, streptococcus pneumoniae, klebsiella pneumonia, staphylococcus aureus, eschersichia coli, enterobacter, proteus and streptococcus faecalis. exceptions include anaerobic bacteria. mycobacterium tuberculosis, neisseria gonorrhoeae, pseudomonas aeruginosa and treponema pallidum. prophylaxis of recurrent urinary tract infections. consideration should be given to official guidance on the appropriate use of antibacterial agents

Storbritannia - engelsk - myHealthbox

milpharm limited - trimethoprim - tablets - 100mg - treatment of susceptible infections caused by trimethoprim sensitive organisms including most gram-positive and gram-negative aerobic organisms, including haemophilus influenzae, streptococcus pneumoniae, klebsiella pneumonia, staphylococcus aureus, eschersichia coli, enterobacter, proteus and streptococcus faecalis. exceptions include anaerobic bacteria. mycobacterium tuberculosis, neisseria gonorrhoeae, pseudomonas aeruginosa and treponema pallidum. prophylaxis of recurrent urinary tract infections. consideration should be given to official guidance on the appropriate use of antibacterial agents

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - trimethoprim 1 mg in 1 ml - trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenza and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

USA - engelsk - NLM (National Library of Medicine)

proficient rx lp - trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - trimethoprim 1 mg in 1 ml - trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenza and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.